Tessera
Folgen

DOD OCA

@ocacademy.bsky.social

An interactive ovarian cancer virtual academy providing intensive mentoring, national networking, and a peer group for junior faculty funded by the CDMRP/DOD. https://www.med.upenn.edu/dodovariancanceracademy/

13 Posts15 Follower10 Folgt
DOD OCA@ocacademy.bsky.social · 5mo ago

The Helene Harris Memorial Trust (HHMT) International Forum on Ovarian Cancer met last year to discuss the latest in the field. It sparked a fantastic review of the latest advances. Check it out! www.nature.com/articles/s41...

Rethinking ovarian cancer III: the past decade and future directions

Nature Reviews Cancer - In this Expert Recommendation, Bowtell and colleagues outline progress made over the last decade in the research and treatment of high-grade serous carcinoma as well as...

nature.com

DOD OCA@ocacademy.bsky.social · 5mo ago

OCA ECIs @vermalab-washu.bsky.social and Dr. Soong, and Dean Ken Nephew highlight new spatial multiomics findings defining 4 STIC subtypes (PIMD), emphasizing precursor heterogeneity and implications for HGSC. pubmed.ncbi.nlm.nih.gov/41923499/

Not All STICs Are Equal: Unraveling the Implications of Precursor Heterogeneity - PubMed

Serous tubal intraepithelial carcinomas (STIC) are precursors of high-grade serous carcinoma (HGSC), the deadliest subtype of ovarian carcinoma. To establish clinically actionable strategies against these lesions, a better understanding of the mutational, transcriptional, and genetic/epigenetic alte …

pubmed.ncbi.nlm.nih.gov

DOD OCA@ocacademy.bsky.social · 10mo ago

OCA ECI alum Jogender Tushir-Singh's lab shows that, unlike in macaques, human TIGIT isn't cleaved into a soluble decoy. This may explain why TIGIT antibodies have struggled in clinical trials. Read all about it below: www.sciencedirect.com/science/arti...

An evolutionary T119R substitution in the macaque T-cell immunoreceptor TIGIT enables proteolytic shedding and reveals clinical antibody vulnerabilities

Despite being a promising target for cancer immunotherapy, several TIGIT (T-cell immunoreceptor with immunoglobulin and ITIM domain) antibodies have b…

sciencedirect.com

DOD OCA@ocacademy.bsky.social · last yr.

Congratulations to DOD OCA ECI Denarda Dangaj Laniti's lab on publication revealing TIL:myeloid crosstalk as a key driver and therapeutic target in BRCA-dependent immune rewiring of recurrent ovarian cancer. www.cell.com/cancer-cell/...

Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer

Ghisoni et al. profile the immune landscape of 697 ovarian cancers (OCs), identifying four immune phenotypes linked to prognosis and treatment response. The study demonstrates that BRCA-dependent TIL:...

cell.com

DOD OCA@ocacademy.bsky.social · last yr.

Congratulations to DOD OCA alum Jogender Tushir-Singh on recent publication showing how a human-specific mutation in FasL makes us more susceptible to cancer. www.nature.com/articles/s41...

Evolutionary regulation of human Fas ligand (CD95L) by plasmin in solid cancer immunotherapy - Nature Communications

Fas ligand (FasL) regulates immunotherapeutic cancer-cell death. Here, the authors show a human-specific amino-acid substitution which renders human FasL more susceptible for plasmin cleavage and is r...

nature.com

DOD OCA@ocacademy.bsky.social · last yr.

Congratulations to OCA alumni Drs. Dmitriy Zamarin and Juan Cubillos-Ruiz, and Deputy Dean @rdrapkin8-penn.bsky.social, on being Pershing Square Foundation Ovarian Cancer Challenge Grant recipients! pershingsquarephilanthropies.org/news/the-per...

The Pershing Square Foundation Launches $5.25M Ovarian Cancer Challenge Grant to Tackle One of the Deadliest and Most Underfunded Women's Cancers — Pershing Square Philanthropies

Pershing Square Philanthropies - we bet on innovative leaders solving humanity’s big societal, environmental, and health challenges.

pershingsquarephilanthropies.org

DOD OCA@ocacademy.bsky.social · 2y ago

The POTEE-ntial is huge! More amazing work by our ECI Marion Curtis, uncovering TTLL8, POTEE, & PKMYT1 as new tumor antigens. pmc.ncbi.nlm.nih.gov/articles/PMC...

Identification of TTLL8, POTEE, and PKMYT1 as immunogenic cancer-associated antigens and potential immunotherapy targets in ovarian cancer

Most high-grade serous ovarian cancers (OC) do not respond to current immunotherapies. To identify potential new actionable tumor antigens in OC, we performed immunopeptidomics on a human OC cell line...

pmc.ncbi.nlm.nih.gov